| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRRC34 |
| Uniprot No | Q8IZ02 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-419aa |
| 活性数据 | MGSSREAARAPARSPAWASTQASTPGAALAVQRESPESGLQKHYSNLCMEKSQKINPFILHILQEVDEEIKKGLAAGITLNIAGNNRLVPVERVTGEDFWILSKILKNCLYINGLDVGYNLLCDVGAYYAAKLLQKQLNLIYLNLMFNDIGPEGGELIAKVLHKNRTLKYLRMTGNKIENKGGMFFAAMLQINSSLEKLDLGDCDLEESTVHVGRMLKENHCLVALHMCKHDIKNSGIQQLCDALYLNSSLRYLDVSCNKITHDGMVYLADVLKSNTTLEVIDLSFNRIENAGANYLSETLTSHNRSLKALSVVSNNIEGEGLVALSQSMKTNLTFSHIYIWGNKFDEATCITYSDLIQMGCLKPDNTDVEPFVVDGRVYLAEVSNGLKKHYYWTSTYGESYDHSSNAGFALVPVGQQP |
| 分子量 | 72.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于假设的重组人LRRC34蛋白相关文献示例(注意：以下内容为虚构，用于展示格式和可能的关联研究方向，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *LRRC34 promotes hepatocellular carcinoma progression by modulating TGF-β signaling*
**作者**: Yuan, X. et al. (2022)
**摘要**: 该研究利用重组人LRRC34蛋白，发现其通过与TGF-β受体结合增强SMAD磷酸化，促进肝癌细胞迁移和侵袭，提示LRRC34在肿瘤转移中的潜在作用。
2. **文献名称**: *Crystal structure of human LRRC34 reveals a conserved leucine-rich repeat motif*
**作者**: Xu, L. et al. (2021)
**摘要**: 通过表达并纯化重组人LRRC34蛋白，解析其晶体结构，揭示其LRR结构域与病原体识别蛋白的相似性，为研究其在先天免疫中的功能提供结构基础。
3. **文献名称**: *LRRC34 interacts with TLR4 and regulates inflammatory response in macrophages*
**作者**: Li, J. et al. (2023)
**摘要**: 研究发现重组人LRRC34蛋白通过结合Toll样受体4(TLR4)抑制NF-κB激活，减弱巨噬细胞炎症因子释放，表明其可能作为免疫应答的负调控因子。
4. **文献名称**: *Expression and functional characterization of recombinant human LRRC34 in vitro*
**作者**: Chen, M. et al. (2020)
**摘要**: 利用哺乳动物表达系统制备重组人LRRC34蛋白，证实其在HEK293细胞中促进ERK信号通路活化，并参与细胞增殖调控。
---
提示：以上为模拟示例，实际研究中LRRC34的研究可能较为有限，建议通过PubMed或Google Scholar检索最新文献，结合关键词“LRRC34”和“recombinant protein”筛选结果。
The human leucine-rich repeat-containing protein 34 (LRRC34) is a member of the leucine-rich repeat (LRR) superfamily, characterized by repetitive structural motifs involved in protein-protein interactions, signal transduction, and cellular adhesion. Though its precise biological functions remain understudied, LRRC34 is hypothesized to participate in immune regulation, extracellular matrix organization, or intracellular signaling pathways based on conserved structural features and homology with related LRR proteins. The protein’s LRR domains suggest a potential role in molecular recognition or scaffolding, which may be critical for modulating cellular responses to environmental cues.
Recombinant human LRRC34 protein is engineered using heterologous expression systems (e.g., Escherichia coli or mammalian cell lines) to enable functional and structural studies. Its recombinant form allows researchers to investigate interactions with binding partners, screen for therapeutic compounds, or explore its involvement in diseases like cancer or autoimmune disorders. Current research on LRRC34 is limited, emphasizing the need for further exploration into its physiological roles, post-translational modifications, and disease relevance. Advances in this area could uncover novel therapeutic targets or biomarkers, aligning with growing interest in LRR proteins as modulators of cellular pathways.
×
